Gastroenterology Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Gastrointest Endosc. 2011 Jun;73(6):1189-96. doi: 10.1016/j.gie.2011.01.053. Epub 2011 Mar 21.
EUS-guided FNA is an efficacious technique for sampling intraintestinal and extraintestinal mass lesions. However, cytology has limitations to its final yield and accuracy, which may be overcome if histological specimens are provided to the pathologist.
To evaluate feasibility, yield, and diagnostic accuracy of a newly developed 19-gauge, fine-needle biopsy (FNB) device.
Multicenter, pooled, cohort study.
Five medical centers.
This study involved 109 consecutive patients with 114 intraintestinal or extraintestinal mass lesions and/or peri-intestinal lymph nodes.
EUS-guided FNB (EUS-FNB) with a newly developed, 19-gauge, FNB device.
Percentage of cases in which pathologists classified the sample quality as optimal for histological evaluation and the overall diagnostic accuracy compared with a composite criterion-standard diagnosis.
We evaluated 114 lesions (mean [± standard deviation] size 35.1 ± 18.7 mm; 84 malignant [73.7%] and 30 [26.3%] benign). EUS-FNB was technically feasible in 112 lesions (98.24%). Sample quality was adequate for full histological assessment in 102 lesions (89.47%). In 98 cases (85.96%), diagnosis proved to be correct according to criterion-standard diagnosis. Sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy for diagnosis of malignancy were 90.2%, 100%, 100%, 78.9%, and 92.9%, respectively.
Use of a surrogate criterion-standard diagnosis, including clinical follow-up when no surgical specimens were available, mainly in benign diagnoses.
Performing an EUS-FNB with a new 19-gauge histology needle is feasible for histopathology diagnosis of intraintestinal and extraintestinal mass lesions, offering the possibility of obtaining a core sample for histological evaluation in the majority of cases, with an overall diagnostic accuracy of over 85%.
EUS 引导下的 FNA 是一种有效的技术,用于对肠道内和肠道外的肿块病变进行取样。然而,细胞学在最终产量和准确性方面存在局限性,如果向病理学家提供组织学标本,这种局限性可能会得到克服。
评估一种新开发的 19 号细针活检(FNB)设备的可行性、产量和诊断准确性。
多中心、汇总、队列研究。
五家医疗中心。
这项研究涉及 109 例连续的肠道内或肠道外肿块病变和/或周围肠道淋巴结患者,共 114 例。
EUS 引导下的 FNB(EUS-FNB),使用新开发的 19 号 FNB 设备。
病理学家将样本质量分类为用于组织学评估的最佳状态的病例百分比,以及与综合标准诊断相比的总体诊断准确性。
我们评估了 114 个病变(平均[±标准差]大小为 35.1±18.7mm;84 个恶性[73.7%]和 30 个良性[26.3%])。112 个病变(98.24%)在技术上是可行的。在 102 个病变中(89.47%),样本质量足以进行全面的组织学评估。在 98 例(85.96%)病例中,根据标准诊断证明诊断正确。恶性肿瘤诊断的敏感性、特异性、阳性预测值、阴性预测值和总体准确性分别为 90.2%、100%、100%、78.9%和 92.9%。
使用替代标准诊断,包括在没有手术标本时进行临床随访,主要用于良性诊断。
使用新的 19 号组织学针进行 EUS-FNB 对于肠道内和肠道外肿块病变的组织病理学诊断是可行的,为大多数病例提供了进行组织学评估的核心样本的可能性,总体诊断准确性超过 85%。